Publication | Closed Access
Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
25
Citations
0
References
2022
Year
Phase 1/2Lymphoid NeoplasiaHematological MalignancyMedicinePharmacologyPathologyCovalent Btk-inhibitor Pre-treatedPharmacotherapyCancer TreatmentBruin StudyOncologyRadiation Oncology
No additional data available for this publication yet. Check back later!